Paradigm Biopharmaceuticals has announced the completion of enrolment in its pivotal Phase 3 trial of Zilosul injectable pentosan polysulfate sodium for knee osteoarthritis, a milestone that moves the company into the next phase of clinical and corporate catalysts. …
Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment
June 15, 2026 Australian Biotech
Latest Video
New Stories
-
An institution dominated by very clever people, but where is the wisdom?
August 14, 2026 - - Latest News -
A plain language version of these dreadful and useless documents
August 14, 2026 - - Latest News -
CUREator+ backs six Australian startups with $13.5 million to advance new health technologies
August 13, 2026 - - Australian Biotech -
Medicines Australia appoints former AbbVie executive to key leadership role
August 13, 2026 - - Latest News -
VVMF and Optosleep partner to advance Australian gene therapy for sleep apnoea
August 13, 2026 - - Latest News -
Survey exposes deep gaps in neurological care across Australia
August 13, 2026 - - Latest News -
Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product
August 13, 2026 - - Latest News